These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26071113)

  • 1. Bisphosphonate treatment of children and adults with osteogenesis imperfecta: unanswered questions.
    Brizola E; Shapiro JR
    Calcif Tissue Int; 2015 Aug; 97(2):101-3. PubMed ID: 26071113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
    Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
    J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of osteogenesis imperfecta with bisphosphonates].
    Tau C
    Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hearing in bisphosphonate-treated children with osteogenesis imperfecta: our experience in thirty six young patients.
    Ting TH; Zacharin MR
    Clin Otolaryngol; 2012 Jun; 37(3):229-33. PubMed ID: 22708940
    [No Abstract]   [Full Text] [Related]  

  • 5. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series.
    Schwartz S; Joseph C; Iera D; Vu DD
    J Can Dent Assoc; 2008; 74(6):537-42. PubMed ID: 18644240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of bisphosphonate treatment on the radiological features of osteogenesis imperfecta in children].
    Chigladze TT; Zhvaniia MA; Bekua MV
    Georgian Med News; 2006 Feb; (131):62-5. PubMed ID: 16575136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle.
    Tsimicalis A; Boitor M; Ferland CE; Rauch F; Le May S; Carrier JI; Ngheim T; Bilodeau C
    Eur J Pediatr; 2018 Jun; 177(6):891-902. PubMed ID: 29637375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
    Aström E; Magnusson P; Eksborg S; Söderhäll S
    Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta.
    Vuorimies I; Mäyränpää MK; Valta H; Kröger H; Toiviainen-Salo S; Mäkitie O
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1333-1339. PubMed ID: 28323993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oesteogenesis imperfecta--genetics, diagnosis and medical treatment].
    Brixen KT; Illum NO; Hansen B; Lund AM; Mosekilde L
    Ugeskr Laeger; 2007 Jan; 169(1):30-4. PubMed ID: 17217883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
    Biggin A; Munns CF
    Curr Osteoporos Rep; 2017 Oct; 15(5):412-418. PubMed ID: 28823022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate treatment of pediatric bone disease.
    Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
    Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
    Sousa T; Bompadre V; White KK
    J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
    Shah I; Johari A
    Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta.
    Kamoun-Goldrat A; Ginisty D; Le Merrer M
    Eur J Oral Sci; 2008 Jun; 116(3):195-8. PubMed ID: 18471236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.